Devonyu/iStock via Getty Images Processa Pharmaceuticals ( NASDAQ: PCSA ) shares shot up 35% in post-market trading Wednesday after the company said the first patient had been dosed in a Phase 2 study of its drug candidate NGC-Cap in the treatment of metastatic breast cancer. Processa (.
Back to Health Page
